{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:52:36Z","timestamp":1786719156105,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijp.ijp_230_16","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T04:33:38Z","timestamp":1552970018000},"page":"17","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach"],"prefix":"10.4103","volume":"51","author":[{"given":"Urmila","family":"Thatte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChennaKeshava","family":"Reddy Sannala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surulivelrajan","family":"Mallayasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayyappa","family":"Chaturvedula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivrutti","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Gogtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.254582-1","first-page":"376","volume-title":"The reality of using primaquine","author":"Burgoine","year":"2010","journal-title":"Malar J"},{"key":"key-10.4103\/0253-7613.254582-2","first-page":"937","volume-title":"Primaquine revisited six decades after its discovery","author":"Vale","year":"2009","journal-title":"Eur J Med Chem"},{"key":"key-10.4103\/0253-7613.254582-3","unstructured":"Guidance for Industry. Population Pharmacokinetics. U.S. Department of Health and Human Services. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM072137.pdf. [Last accessed on 2013 Nov 25]."},{"key":"key-10.4103\/0253-7613.254582-4","first-page":"488","volume-title":"Population based pharmacokinetic analysis: Why do we need it; what is it; and what has it told us about anaesthetics?","author":"Wright","year":"1998","journal-title":"Br J Anaesth"},{"key":"key-10.4103\/0253-7613.254582-5","doi-asserted-by":"crossref","unstructured":"Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM, et al. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 1985;19:745-50.","DOI":"10.1111\/j.1365-2125.1985.tb02709.x"},{"key":"key-10.4103\/0253-7613.254582-6","doi-asserted-by":"crossref","unstructured":"Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, et al. Pharmacokinetics of primaquine in man. II. Comparison of acute vs. chronic dosage in Thai subjects. Br J Clin Pharmacol 1985;19:751-5.","DOI":"10.1111\/j.1365-2125.1985.tb02710.x"},{"key":"key-10.4103\/0253-7613.254582-7","first-page":"205","volume-title":"Pharmacokinetics of primaquine in patients with P.vivax malaria","author":"Bhatia","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.254582-8","first-page":"767","volume-title":"Pharmacokinetics of a single dose (15 mg) primaquine in chronic kidney disease patients undergoing haemodialysis","author":"Sridharan","year":"2014","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/0253-7613.254582-9","first-page":"441","volume-title":"Pharmacokinetics of primaquine in man: Identification of the carboxylic acid derivative as a major plasma metabolite","author":"Mihaly","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.254582-10","first-page":"99","volume-title":"Renal failure, drug pharmacokinetics and drug action","author":"Fabre","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/0253-7613.254582-11","first-page":"432","volume-title":"Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: Feasibility of abbreviated high-dose regimens for radical cure of vivax malaria","author":"Moore","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.254582-12","first-page":"643","volume-title":"Flip-flop pharmacokinetics \u2013 Delivering a reversal of disposition: Challenges and opportunities during drug development","author":"Y\u00e1\u00f1ez","year":"2011","journal-title":"Ther Deliv"},{"key":"key-10.4103\/0253-7613.254582-13","unstructured":"Bonate PL. Nonlinear mixed effect models: Theory. In: Pharmacokinetic and Pharmacodynamic Modeling and Stimulation. New York: Springer; 2006."},{"key":"key-10.4103\/0253-7613.254582-14","first-page":"36","volume-title":"A leisurely look at the bootstrap, the jackknife and cross validation","author":"Efron","year":"1983","journal-title":"Am Stat"},{"key":"key-10.4103\/0253-7613.254582-15","first-page":"486","volume-title":"Stability and performance of a population pharmacokinetic model","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.254582-16","first-page":"399","volume-title":"Plasma kinetics and urinary excretion of primaquine in man","author":"Greaves","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.254582-17","first-page":"330","volume-title":"Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction","author":"Kulkarni","year":"2013","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0253-7613.254582-18","first-page":"1147","volume-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.254582-19","first-page":"562","volume-title":"Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine","author":"Clyde","year":"1977","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.4103\/0253-7613.254582-20","first-page":"621","volume-title":"Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: A preliminary report","author":"Alving","year":"1960","journal-title":"Bull World Health Organ"},{"key":"key-10.4103\/0253-7613.254582-21","first-page":"418","volume-title":"Rationale for recommending a lower dose of primaquine as a plasmodium falciparum gametocytocide in populations where G6PD deficiency is common","author":"White","year":"2012","journal-title":"Malar J"},{"key":"key-10.4103\/0253-7613.254582-22","first-page":"447","volume-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"key-10.4103\/0253-7613.254582-23","first-page":"220","volume-title":"Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria","author":"Bangchang","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.4103\/0253-7613.254582-24","first-page":"249","volume-title":"Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity","author":"Stepniewska","year":"2008","journal-title":"Malar J"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:44:35Z","timestamp":1786715075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_230_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"alternative-id":["254582"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_230_16","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}